Cbd oil for autism 2022

CBD-enriched cannabis for autism spectrum disorder: an experience of a single center in Turkey and reviews of the literature

Autism spectrum disorder is a neurodevelopmental disorder characterized by deficits in communication, social interaction, restricted interest, and repetitive behaviors. Although more cases are being diagnosed, no drugs are approved to treat the core symptoms or cognitive and behavioral problems associated with autism. Therefore, there is an urgent need to develop an effective and safe treatment.

Objective

In this study, we aim to share our 2-year experience with CBD-enriched cannabis treatment in autism and review the latest studies.

Materials and methods

The study included 33 (27 males, six females) children diagnosed with autism spectrum disorder who were followed up between January 2018 and August 2020. The mean age was 7.7 ± 5.5 years. The average daily dosage of cannabidiol (CBD) was 0.7 mg/kg/day (0.3–2 mg/kg/day). The median duration of treatment was 6.5 months (3–28 months). The preparations used in this study contained full-spectrum CBD and trace elements tetrahydrocannabinol (THC) of less than 3%.

Results

The outcomes were evaluated before and after treatment based on clinical interviews. At each follow-up visit, parents were asked to evaluate the effectiveness of the CBD-enriched cannabis treatment. According to the parents’ reports, no change in daily life activity was reported in 6 (19.35%) patients. The main improvements of the treatment were as follows: a decrease in behavioral problems was reported in 10 patients (32.2%), an increase in expressive language was reported in 7 patients (22.5%), improved cognition was reported in 4 patients (12,9%), an increase in social interaction was reported in 3 patients (9.6%), and a decrease in stereotypes was reported in 1 patient (3.2%). The parents reported improvement in cognition among patients who adhered to CBD-enriched cannabis treatment for over two years. The antipsychotic drug could be stopped only in one patient who showed mild ASD symptoms. No change could be made in other drug use and doses. Additionally, this study includes an extensive review of the literature regarding CBD treatment in autism spectrum disorder. According to recent studies, the average dose of CBD was 3.8±2.6 mg/kg/day. The ratio of CBD to THC in the used preparations was 20:1. The most significant improvements were seen in the behavioral problems reported in 20–70% of the patients.

Conclusion

Using lower doses of CBD and trace THC seems to be promising in managing behavioral problems associated with autism. In addition, this treatment could be effective in managing the core symptoms and cognitive functions. No significant side effects were seen at the low doses of CBD-enriched cannabis when compared to other studies.

Background

Autism spectrum disorder (ASD) is a neurodevelopmental disorder that varies in severity and is characterized by deficits in communication, social interaction, restricted interest, and repetitive behaviors (Fusar-Poli et al. 2020). During the last three decades, there has been a threefold increase in the number of children diagnosed with ASD (Lihi Bar-Lev Schleider et al. 2019). Currently, it affects up to 1 in 54 individuals (Maenner et al. 2020). Cooccurring medical conditions such as epilepsy, intellectual disability, and behavior problems occur in these individuals (Pretzsch et al. 2019a; Pretzsch et al. 2019b).

The etiopathogenesis of ASD remains largely unknown. Several genetic, perinatal, and environmental factors seem to be involved. Some researchers have evidenced an imbalance in the endogenous neurotransmission system, such as the serotoninergic, γ aminobutyric acid (GABA), and endocannabinoid system (ECS), which regulate functions such as emotional responses and social interactions typically impaired in ASD (Fusar-Poli et al. 2020).

Endocannabinoids (eCBs) and their receptors are present in the nervous system, connective tissue of internal organs, glands, and immune system. Cannabinoid receptor 1 (CB1) is a G protein-coupled receptor (GPR) that is found mainly in the central nervous system (Mc Partlan et al. 2014). In mammals, high concentrations of CB1 are found in the brain area that regulates appetite, memory, fear extinction, motor responses, and postures such as the hippocampus, basal ganglia, basolateral amygdala, hypothalamus, and cerebellum (Aran et al. 2019; Mc Partlan et al. 2014). CB1 can also be found in nonneuronal cells. Data indicate that cannabinoid receptor type 2 (CB2) is linked to a variety of immune functional events. However, it may play a functionally relevant role in the central nervous system (Aran et al. 2019; Bridgemanan and Abazia 2017).

There are two endogenous cannabinoids, N-arachidonoylethanolamine (anandamide) and two arachidonoylglycerols (2-AG). The ECS has been broadened by discovering new secondary receptors, ligands, and ligand metabolic enzymes, including transient receptor potential cation channel subfamily V member 1 (TRPV1) (Mc Partlan et al. 2014).

Anandamide and 2-AG can act via CB1 and CB2 receptors and exert a range of biological effects in central and peripheral cells. Anandamide is broken down by fatty acid amide hydrolase (FAAH); inhibitors of FAAH lead to an increase in anandamide. CBD act as an inhibitor of FAAH (Bridgemanan and Abazia 2017). Endocannabinoid signaling occurs in a retrograde direction; that is, signaling is initiated in postsynaptic neurons and acts upon presynaptic terminals. In contrast to classical neurotransmitters, eCBs are not stored. They are produced on demand upon stimulation of postsynaptic cells (Aran et al. 2019; Zamberletti et al. 2017).

Interestingly, CBD displays a low affinity for CB1 and CB2 receptors. CBD facilitates excitatory glutamate and inhibitory GABA neurotransmission across the brain through agonism at the TRPV1 receptor (Pretzsch et al. 2019a; Mc Partlan et al. 2014). Additionally, CBD can increase GABAergic transmission by antagonizing G protein-coupled receptor 55 (GPR55), especially in the basal ganglia. CBD is thought to be an agonist at prefrontal serotonin 5-HT1A receptors (Castillo et al. 2012) (Fig. 1).

CBD and mechanism of action. CBD, cannabidiol; FAAH, fatty acid amide hydrolase CB, cannabinoid receptor; TRPV1, transient receptor potential cation channel subfamily V member 1; PPAR-γ, peroxisome proliferator-activated receptor-gamma; GPR, G protein-coupled receptor; GPR55, G protein-coupled receptor 55; 5-HT1A, serotonin 5HT receptor; MC4R, melanocortin 4 receptor; ROS, reactive oxygen species

Another mechanism of action can be via vasopressin and oxytocin. The presence of oxytocin in the CSF seems to originate from neuronal oxytocinergic extensions to the limbic system, brain stem, and spinal cord. Oxytocin receptors are distributed in different parts of the central nervous system, such as the basal ganglia, limbic system, thalamus and hypothalamus, and brain stem. Oxytocin modulates social behavior, motor function, pain control, memory and learning, eating behavior, stress and anxiety, and emotional processing. Oxytocin administration reduces stress and anxiety and depression in animal models. This effect seems to be modulated at least partly by the effects of oxytocin on the hypothalamic-pituitary-adrenal (HPA) axis and the opioidergic and dopaminergic systems in limbic brain structures. Several animal model studies support the role of oxytocin in improving social behavior, an effect that appears to involve the melatoninergic and endocannabinoid systems, specifically an increase in social interactions produced by agonism at the melanocortin four receptor (MC4R (Russo et al. 2005; Dos Santos et al. 2019). CBD leads to enhancement in the release of vasopressin and oxytocin; thus, it could positively affect ASD core symptoms. Studies have shown that oxytocin administration to patients with ASD improves social interactions, reduces classic repetitive behavior, and increases eye contact (Weia et al. 2015). Another mechanism of action of CBD is to act as a dopamine receptor antagonist, which can facilitate its use as an antipsychotic (Dos Santos et al. 2019; Weia et al. 2015).

CBD may act as a neuroprotectant against mitochondrially acting toxins (Davies and Bhattacharyya 2019; Bartova and Birmingham 1976). The highly lipophilic aspect of CBD gives them access to intracellular sites of action. Many studies have suggested mitochondria as targets for CBD, and many theories are based on this idea; one of these theories is that the outer mitochondrial membrane has CB1 receptors. This theory reveals that CBD affects the function of the cells by establishing homeostasis and influencing mitochondria and energy production (Bartova and Birmingham 1976; Ryan et al. 2009).

THC is known to be a major psychoactive component of Cannabis. THC is a partial agonist at CB1 and CB2 (Ryan et al. 2009). Signals through transducing G-proteins and activation of these G-proteins by THC cause inhibition of adenyl cyclase activity, the closing of voltage-gated calcium channels, and the opening of inward rectifying potassium channels. The psychoactive nature of THC limits its use due to side effects. However, a varied mixture of THC with other phytocannabinoids with very weak or no psychoactivity quality has started to be used as a therapeutic drug in humans (Bloomfield et al. 1982; Rodríguez De Fonseca et al. 1992). In this study, we aim to share our 2-year experiences with CBD-enriched cannabis treatment in autism and review the latest studies.

Methods and materials

Patients

This research was conducted in accordance with the Declaration of Helsinki at the Pediatric Clinics of Neurology in Istanbul. CBD-enriched cannabis treatment was started in 54 patients who were diagnosed with ASD. The study included 33 (27 males, six females) children diagnosed with autism spectrum disorder who were followed up between January 2018 and August 2020. The diagnosis of ASD was based on DSM V criteria (American Psychiatric Association 2013). Twenty-one participants refused to participate in this study. The most common reasons for not participating in the study were fear of adverse effects, cost of CBD-enriched cannabis, bitter taste, and behavioral problems. The mean age of the non-participating 21 children was 7.2 ± 4.2. Ten patients had mild, while 11 had severe autism according to the DSM V. Four patients were female, and 17 were male. Three children had abnormal EEG, and one was diagnosed with epilepsy, and he was on valproic acid treatment. Three patients attended mainstream schools and received their education there, while eighteen patients had intellectual disabilities. All non-participating 21 ASD patients used antipsychotic drugs. Sixteen patients used risperidone, and five patients used aripiprazole. The median duration of antipsychotic drug administration was 8.2 ± 2.6 months. The median duration of follow-up was 4.4 1 ± 1 years.

Informed consent was obtained from the parents of all children participating in the study. The mean age of the participating 33 children was 7.7 ± 5.5. Fifteen patients had mild autism, while 18 had severe autism according to the DSM V. Three patients were diagnosed with epilepsy before starting CBD-enriched cannabis; two of them used oxcarbazepine, while one used valproic acid. Seven patients had abnormal electroencephalography (EEG) results without any episodes of previous seizures. Five patients attended mainstream schools and received their education there, while twenty-eight patients had intellectual disabilities and attended schools that catered to special educational needs. Two patients were using CBD-enriched cannabis for over two years. There was no predefined duration of this treatment in our patients. All ASD patients used antipsychotic drugs. Twenty-six patients used risperidone, and seven patients used aripiprazole. The median duration of antipsychotic drug administration was 8.5 ± 2.3 months. All the patients were provided with psychosocial treatment. The median duration of follow-up was 4.6 ± 1.3 years. There were no significant differences between the 2 group profiles (participating and non-participating) regarding sex ratio, median age, and autism severity.

Treatment

The legal basis for using cannabis-related drugs is not fully apparent in Turkey, and a maximum of 0.3% THC is allowed to be used in these preparations. Due to the lack of availability and difficulty of access to these therapeutic preparations, various cannabis strains of CBD-enriched cannabis extracts have been used. The two CBD-enriched cannabis brands used were CBDistillery and CBDodgamax. Both had similar available forms of drops of 500, 1000, and 2500 mg/30 ml and contained full-spectrum CBD and trace THC. These drops were started with dosages that were calculated according to the patient’s body weight, with one sublingual drop twice a day and one drop every three days. The average daily CBD-enriched cannabis dose was 0.7 mg/kg (0.3–2 mg/kg). No patient was given a daily maintenance dose of CBD higher than 40 mg/day. The average duration of treatment was 6.5 months (3–28 months).

See also  Cbd hemp oil for shingles

Results and outcomes

The outcomes were evaluated before and after treatment based on clinical interviews. At each follow-up visit, parents were asked to assess the overall effectiveness of CBD-enriched cannabis treatment. According to the parents’ reports, no change in daily life activity was reported in 6 (19.35%) patients. The main improvements of the treatment were as follows: a decrease in behavioral problems was reported in 10 patients (32.2%), an increase in expressive language was reported in 7 patients (22.5%), improved cognition was reported in 4 patients (12.9%), an increase in social interaction was reported in 3 patients (9.6%), and a decrease in stereotypes was reported in 1 patient (3.2%). The parents reported improvement in cognition in patients who adhered to CBD-enriched cannabis treatment for over two years. The antipsychotic drug could be stopped only in one patient who showed mild ASD symptoms. No change could be made in other drug use and doses.

Discontinuation and side effects

A 13-year-old male patient with severe autism had generalized seizures after using 5 mg sublingual CBD, and the drug was discontinued because of this side effect. The epileptic seizures persisted despite the discontinuation of the treatment. Interictal sleep EEG showed symmetrical bilateral frontotemporal sharp-slow wave complexes. The patient was regularly treated with valproic acid and remained seizure-free after starting this antiepileptic drug. CBD-enriched cannabis was also discontinued in a nine-year-old male patient with severe autism after two weeks because of a significant increase in stereotypes. No change in laboratory values related to CBD-enriched cannabis was found in any patient.

Restlessness was the only reported side effect in 7 (22%) out of 31 patients who continued treatment for at least three months, and the CBD-enriched cannabis dose was reduced in these patients. As the amount was reduced, restlessness decreased.

A review of other studies

The popularity of CBD-enriched cannabis for the treatment of autism is increasing. Scoping reviews were done to achieve a broad and thorough examination of the literature in this area. Aran et al. (2019) were the first to retrospectively assess CBD-enriched cannabis effects on 60 children with ASD and severe behavioral problems using an open-label cohort study. The mean age was 11.8 ± 3.5 years; 82% of patients used psychiatric medications; 77% of patients had low cognitive function; and 23.3% of patients had epilepsy. All the children received CBD and THC in a 20:1 ratio. The mean total daily dose was 3.8 ± 2.6 mg/kg/day CBD and 0.29 ± 0.22 mg/kg/day THC for children who received three daily doses (n=44) and 1.8 ± 1.6 mg/kg/day CBD and 0.22 ± 0.14 mg/kg/day THC for children who received two daily doses (n=16). The doses were titrated over 2–4 weeks. The mean follow-up period was 10.9 ± 2.3 months. Efficacy was assessed using the Caregiver Global Impression of Change (CaGI) scale. Considerable improvement in behavioral problems was noticed in 61% of patients. Improvement in anxiety and communication problems was seen in 39 and 47%, respectively. Based on these promising results, Aren et al. launched a new placebo-controlled crossover trial. This study is ongoing, and new outcomes will be addressed in future publications (Aran et al. 2019).

Another study was conducted to evaluate the efficacy and safety of CBD-enriched cannabis effects on autism. This prospective, open-label study was carried out by Lihi Bar-Lev Schleider et al. and included 188 patients. The mean age was 12.9 ± 7 years. A total of 14.4% of patients had epilepsy. Most patients used preparations with 30% CBD and 1.5% THC, and the average concentrations of CBD and THC were 79.5 ± 61.5 mg and 4.0 ± 3.0 mg, respectively. After one month of treatment, 179 patients adhered to the treatment, and only 119 patients could be evaluated. Significant improvement was reported in 48.7% of patients, moderate improvement was reported in 31.1% of patients, and no change was reported in 14.3% of patients. Side effects were reported in 5.9% of patients. After 6 months of treatment, 155 patients continued treatment with CBD. Of the latter group, 93 patients responded to the questionnaire, 30.1% reported significant improvement, 53.7% reported moderate improvement, 6.4% reported slight amelioration, and 8.6% of the patients reported no change. Quality of life, mood, and ability to perform daily living activities were evaluated before the treatment and at 6 months. A total of 31.3% of the patients reported good quality of life before treatment. After 6 months, this percentage increased up to 66.8% (Lihi Bar-Lev Schleider et al. 2019).

Paulo Fleury et al. (2019) conducted a prospective, observational, and open-label study with a cohort of 18 autistic patients who received CBD-enriched cannabis (with a CBD-to-THC ratio of 75/1). The average dose of CBD was 4.55 mg/kg/day (a minimum of 3.75 mg and a maximum of 6.45 mg/kg/day). The average THC dose was 0.06 mg/kg/day (a minimum of 0.05 and a maximum of 0.09 mg/kg/day). The mean age was ten years. Fifteen patients adhered to the treatment (10 nonepileptic and five epileptic), and only one patient showed a lack of improvement in autistic behaviors. The most significant improvements were reported for seizures, attention-deficit/hyperactivity disorder, sleep disorders, communication, and social interaction (Paulo Fleury et al. 2019). Barchel et al. (2019) performed an open-label study on 53 autistic children. The median age was 11 (4–22) years; these patients received CBD at a concentration of 30% and a 1:20 ratio of CBD to THC. The median THC interquartile range (IQR) daily dose was 7 (4–11) mg, and the median CBD (IQR) daily dose was 90 (45–143) mg. The median duration of treatment was 66 days (30–588). Self-injury and rage attacks improved by 67.6% and worsened by 8.8%, respectively. Improvement in hyperactivity symptoms was reported in 68.4% of patients, 28.9% reported no change, and 2.6% reported worsening symptoms. Sleep problems improved by 71.4% and worsened by 4.7%. There was an improvement in anxiety in 47.1% and worsening in 23.5% of patients (Barchel et al. 2019). Mojdeh Mostafavi et al. (2020) reported positive effects of cannabis in ASD, especially in aggressive and self-injurious behaviors (Mostafavi and Gaitanis 2020). McVige et al. (2020) carried out an important retrospective and open-label study on 20 patients with ASD (6 with epilepsy and 14 with pain). These patients were on cannabis treatment. The study reported very significant positive outcomes. The Autism/Caregiver Global Impression of Change (ACGIC) scale revealed improvements in sleep, mood, and aggression toward the self or others; there were also improvements in patient communication abilities and attention/concentration (McVige et al. 2020).

According to Aren et al.’s study, adverse events such as hypervigilance aggravated sleep disturbances in 14% of patients. This side effect was resolved by omitting or adjusting the evening doses. Irritability in 9% and loss of appetite in 9% were seen. A thirteen-year-old girl received 6.5 mg/kg/day CBD and no other medications; when she gradually increased the THC dose up to 0.72 mg/kg/day, she developed sudden behavioral changes such as unusual vocalization and refusal to sleep and eat for two days. The symptoms resolved when she stopped CBD and THC and received antipsychotic treatment (ziprasidone). After cannabis treatment, psychiatric medications were regulated in most patients; 33% received fewer or lower doses, 24% stopped taking medications, and 8% received more medication or higher doses (Aran et al. 2019). Lihi Bar-Lev Schleider et al. reported mild side effects such as restlessness, sleepiness, dry mouth, and digestion problems (Lihi Bar-Lev Schleider et al. 2019). Paulo Fleury et al. reported that three patients stopped using CBD-enriched cannabis in a period shorter than one month due to side effects (autistic behaviors had worsened in two patients, which might happen due to the unsupervised and sudden cessation of the antipsychotics; one patient had insomnia, irritability, increased heart rate, and worsening of psych-behavioral crises that might be due to the interaction of cannabis with previous prescribed antipsychotic drugs). Mild and transient adverse effects such as sleepiness, moderate irritability, diarrhea, increased appetite, conjunctival hyperemia, and increased body temperature were also reported (Paulo Fleury et al. 2019).

Discussion

In the updated review, preliminary evidence announcing that cannabinoids (compounds with different ratios of CBD and THC) could exert beneficial effects on some ASD-associated symptoms, such as behavioral problems, hyperactivity, and sleep disorders, with a lower number of metabolic and neurological side effects than approved medications. Importantly, treatment with cannabinoids permits a reduction in the number of prescribed drugs and significantly reduces the frequency of seizures in participants with comorbid epilepsy. In this paper, we aimed to make some critical points related to the main findings and mechanisms of action of cannabinoids, such as a decrease in behavioral problems, an increase in the expressive language, an improvement in cognition, and an increase in social interaction when patients used CBD-enriched cannabis at a dose of 0.7 mg/kg (0.3–2 mg/kg), which is lower than the doses reported in other studies. Furthermore, these results are consistent with other studies that suggest that supplementing ASD patients with CBD-enriched cannabis could improve behavioral problems. A dose of 3.8 ± 2.6 mg/kg/day CBD was used in Aren et al.’s study and yielded improvements in anxiety and communication problems. According to Paulo Fleury et al., the average dose of CBD was 4,55 mg/kg/day, and the results showed that only one patient reported no improvement in autistic behaviors. The most significant improvements were reported for seizures, attention-deficit/hyperactivity disorder, sleep disorders, communication, and social interaction. In addition, improvements in expressive language were seen. CBD-enriched cannabis might help children with ASD via several possible mechanisms, including its anxiolytic and antipsychotic properties and its impact on the endocannabinoid system (ECS) and oxytocin (Dos Santos et al. 2019; McVige et al. 2020; Premolia et al. 2019). According to our results, we recommend using lower doses of CBD-enriched cannabis.

CBD use is not devoid of health risks; known risks include liver damage, adverse effects on the male reproductive system, potential drug interactions that may be associated with adverse events or diminished efficacy of approved therapies, and additional unknown health risks. However, the pharmacology of CBD has not been well studied; thus, little is known about both the potential therapeutic benefits and the hazards of short- or long-term use (Leas et al. 2020). According to our study, restlessness was the only mild side effect seen in some patients which was resolved on making some doses adjustments. In addition, generalized seizures after starting CBD-enriched cannabis. And these seizures re-occurred even several months after cessation of CBD treatment, and abnormal EEG results were seen. Therefore, this study cannot make causal inferences on the relation between CBD-enriched cannabis and seizures. Not all patients benefit equally from the use of CBD. The reason why some patients experienced benefits while others experienced side effects could be due to candidate genes that may influence the acute effects of cannabis. Genes posited to have specific influences on cannabis include CNR1, CB2, FAAH, MGL, TRPV1, and GRP55. When some patients have a mutation in these receptors, different results could be seen when cannabis was used (Agrawal and Lynskey 2009). Other studies also reported reversible and some mild side effects, none of which were life-threatening. Most of the side effects were overcome by adjusting the doses. Furthermore, the use of recreational cannabis in adolescents is associated with several risks, including decreased motivation, addiction, mild cognitive decline, and schizophrenia. However, these complications are all attributed to THC. Our study drug was full-spectrum CBD and trace THC. Nevertheless, systematic evaluation of safety data of CBD use in children is still lacking. Future research is recommended that examines the clinical impact of CBD-enriched cannabis. Additionally, rarer side effects were seen in our patients compared to other studies, which could be due to using lower doses of CBD and trace THC (a brief overview of all these studies is given in Tables 1 and 2).

See also  Does cbd oil work for epilepsy in dogs

These preclinical data and the current study results render further exploration of this treatment avenue in controlled studies. Until such evidence is available, physicians should be cautious when using medical cannabis to treat children with ASD since initial reports of promising treatment in children with ASD are often found.

Limitations of the study

The absence of the control study group, the use of various strains of CBD-enriched cannabis extracts, different durations of treatment and dosages, and depending on the reports of the parents instead of standard assessment scales are considered to be the main limitations of the study. The clinical assessments were done with knowledge of the patients’ treatment (it was an open-label case series, not a blinded clinical trial.

Conclusion

Using lower doses of CBD and trace THC seems to be promising in the management of behavioral problems associated with autism. In addition, this treatment could be effective in managing core symptoms and cognitive functions. No significant side effects were seen at the low doses of CBD-enriched cannabis when compared to other studies.

Availability of data and materials

The datasets used and analyzed in this review article are available from the corresponding author upon reasonable request.

The 9 Best CBD Oils for Autism in 2022

Autism Spectrum Disorder (ASD) is a developmental disability that can potentially cause a variety of symptoms for those who place on the spectrum.

Featured CBD Brands:

These can include significant social, communication, and behavioral challenges when compared to those that do not place on the spectrum. Individuals with ASD may behave, communicate, interact, and learn in ways that one might consider to be outside of the norm. Here are some things you may not know:

  • Autism is classified as a “spectrum” disorder. This is due to the fact that there is a wide variation in the type and in the severity of symptoms that people that have placed on the spectrum may experience;
  • Approximately one out of 59 children have been identified as having an Autism Spectrum Disorder, according to the most recent estimates from the Center for Disease Control’s Autism and Developmental Disabilities Monitoring (ADDM) Network;
  • Autism Spectrum Disorder occurs in all racial, ethnic, and socioeconomic groups; however, the likelihood of placing on the spectrum is approximately four times higher among young boys than among young girls;
  • Being diagnosed as having an Autism Spectrum Disorder can occur at any age in life. It is commonly referred to as being a “developmental disorder” because the classic symptoms of Autism Spectrum Disorders will usually first present themselves and be recognized within the first two years of a child’s life. With that said, diagnosis can occur at any age and many people do not find out that they are on the spectrum until later in life;
  • Although there is currently no cure for ASD, many clinical research trials have shown that early intervention treatment can significantly improve a child’s development to put them more in line with their peers, and;
  • Less than 2% of the general population in the United States suffers from epilepsy, but around 33% of people with Autism will also have epilepsy as a comorbidity.

With the challenges that a person that places somewhere on the spectrum may face in their day-to-day lives, one of the best things that can be done to help mitigate any negative impacts that they might experience is to try and help those individuals to handle the symptoms that commonly come with having Autism. Due to this, we wish to offer some products that can be used in a supplementary manner in order to possibly achieve a better quality of life overall.

Why Should You Try CBD if You Have ASD or Are on the Spectrum?

The most well-known and understood medical benefits of Phytocannabinoids (and CBD in particular) on the body are their neuroprotective, anticonvulsant, anti-inflammatory, and pain relieving properties. Additionally, CBD has shown a large amount of medical evidence that it can greatly improve the mood, cognitive function, and focus with regular and proper use. Because of these beneficial properties that CBD commonly provide to users, CBD-based supplements could have a very real impact on an individual with Autism’s life by helping to negate or mitigate some of the physical, emotional and mental side-effects of Autism.

Many people with ASD often experience problems with irritability, hyperactivity, attention issues, anxiety, depression and many of these individuals have trouble falling asleep or having a restful sleep after they do finally manage to fall asleep. Regular and proper CBD use can really assist with all of these problems, by relaxing the user, helping to counteract irritability, helping with focus and attention issues and by helping them to sleep better at night. Because we feel CBD could greatly benefit some individuals with Autism, we have hand-picked the best products from the following ten CBD companies that we think will be the most helpful.

The 9 Best CBD Oils for Autism

1. NuLeaf Naturals

When it comes to high potency, top-of-the-line CBD oil, Nuleaf Naturals tops our list as the best choice. They have a stellar reputation in the field and are known for their dedication to cultivating the highest caliber hemp plants all within the U.S., creating pure CBD products. Their product line is simple: full-spectrum, hemp-derived CBD oil in tincture form. All products are third-party tested with results for every batch available to consumers.

NuLeaf Naturals offers their full-spectrum CBD in several different sizes. Each of the concentrations are the same, 50 milligrams per milliliter. The only difference is the volume of CBD oil. The smallest size is 5 milliliters, and the largest is 100 milliliters. Beginning with a moderate size, like 15 milliliters, can be helpful for a slight decrease in cost per milligram of CBD. We recommended the 725-milligram Full-Spectrum CBD Oil for autism, although any size of their CBD tincture would suffice.

  • Product Types: Tinctures, pet care
  • Our Recommended Product for Autism: 725mg Full-Spectrum CBD Oil

2. Spruce

Spruce is geared toward people who have tried other CBD products in the past and have not seen the results they wanted or expected. Their CBD oil is lab-grade and full-spectrum. This means it is high-quality and includes other components of the hemp plant that work synergistically with CBD. Spruce’s goal is to deliver CBD tinctures and topicals that are potent and effective so that you get value for your money.

The concentration of their tinctures is incredibly high, either 750 or 2,400 milligrams of CBD per bottle, which is much higher than average. For the 750-milligram bottle, each serving contains 25 milligrams of CBD and costs $89. This is a stellar deal considering the potency. The 2,400 milligram bottle costs $269, and each serving supplies a whopping 80 milligrams of CBD. For people with autism, the 2,400-milligram bottle is our choice for the best value CBD, as it is very high in CBD and very reasonably priced.

  • Product Types: Tinctures, topicals, pet care
  • Our Recommended Product for Autism: 2,400mg Lab Grade CBD Oil

3. Kanibi

Kanibi takes pride in its products, and they are committed to creating CBD products that are pure and science-based. All of their CBD products are third-party tested not once, but twice to deliver chemical-free, high-potency, quality products.

They offer an extensive product line, which includes CBD tinctures, creams, gummies, and soft gels. You can expect the same level of precision with each formulation. For people with autism, we recommend Kanibi’s full-spectrum CBD oil, which always contains less than 0.3% THC. It comes in a variety of appetizing flavors using only all-natural flavoring agents. Flavors include skittles, lemon-lime, choco-mint, cinnamon, and also unflavored for those who prefer CBD oil in its most natural form. This CBD oil is in an MCT carrier oil for easy digestion and absorption.

  • Product Types: Tinctures, capsules, gummies, topicals
  • Our Recommended Product for Autism: Organic Full-Spectrum CBD Oil

4. FAB

When choosing a CBD company to buy from, there are a few key things to consider, including organic hemp grown in the U.S., third-party testing, CBD potency, and pricing. FAB CBD checks all these boxes and more. This company consists of members in the health and fitness industry, which lends a level of authenticity. Their products contain all organic hemp-derived CBD, grown in the U.S.

FAB offers a wide array of products, from pet care to vape products to CBD oil tinctures. One of the most impressive products is the 2,400-milligram CBD oil tincture. This is a potent CBD oil: Each dropperful contains 80 milligrams of CBD. Unlike many other CBD tinctures on the market, FAB’s CBD tincture has a very high CBD concentration in every drop. This CBD oil comes in four flavors (plus neutral) and costs $129.

  • Product Types: Tinctures, gummies, topicals, pet care, vape oils
  • Our Recommended Product for Autism: Full-Spectrum Citrus 2,400 CBD Oil

5. Farmacy Bliss

It is clear from the soothing color palette of the packaging what Farmacy Bliss is all about. Their emphasis is on the relaxing, anti-inflammatory, pain-relieving, blissful properties of CBD. They are transparent about their organic farming practices, and they test at every stage of production. Farmacy Bliss’ product range includes vape products, capsules, tinctures, as well as wellness boxes where you can sample several smaller sized products.

The product from Farmacy Bliss that has stolen our attention for autism is the Cherry Abacus CBD vape pen. It contains 350 milligrams of organic, full-spectrum CBD with no added solvents or thinners, which is imperative for safety purposes. The name of the flavor melon gum itself is mouthwatering. In our opinion, it takes home the prize for best tasting CBD product.

  • Product Types: Tinctures, capsules, vape oils
  • Our Recommended Product for Autism: CBD Vape Pen Cherry Abacus

6. The Brothers Apothecary

The Brothers Apothecary have been named as the “Best CBD Tea” by Herb, and they have additionally scored a respectable 93 points out of 100 at the 2018 Portland Dope Cup. The Brothers Apothecary have also been featured in numerous news publications, and consistently receive a large amount of praise for the quality, efficacy, and potency of their many different CBD-based products. Some of the products that you can find in their online store–and in physical specialty stores across the country–include products such as their flagship CBD teas, their topical balms, CBD drink mixes, and CBD tinctures, among others. Each of The Brothers Apothecary’s is artisanally crafted using local, handcrafted, and organic ingredients that are sourced in Portland, Oregon.

See also  Mod for cbd oil reddit

The Brothers Apothecary sends all of their products out for exhaustive third-party laboratory testing, and they use the services of the Green Leaf Lab. Green Leaf Lab is an Oregon-based testing facility and a proud member of the Oregon Bioscience Association (OBA), which is Oregon’s most trusted testing agency for both medicinal cannabis and cannabis-derived products and for CBD products that were extracted from industrial hemp sources. Because of the stringent testing that The Brothers Apothecary’s products undergo, their customers can rest easy with the knowledge that the CBD products that they buy from The Brothers will be of the highest quality possible in purity, safety, and potency.

The product manufactured and sold by The Brothers Apothecary that we most recommend to individuals with Autism is their Focus CBD Essential Oil Roller. This essential oil roller is perfect for individuals that are looking for a CBD product to help with managing Autism and with mitigating the varied problems that can go along with placing on the Autism Spectrum. The Brothers Apothecary’s Focus CBD Essential Oil Roller is a ten-milliliter bottle containing approximately 100 mg of CBD in total. This oil roller contains 100% guaranteed organic and locally sourced essential oils. These essential oils are: sweet almond oil, jojoba oil, tangerine essential oil, clove essential oil, and CBD isolate that was extracted from organic and locally sourced industrial hemp.

All of these essential oils work in conjunction with the CBD isolate in order to provide the user with a boost to their mental acuity and their ability to focus on tasks. A large percentage of people with Autism have complained about having issues with focusing or suffering from “mental fog,” either because Attention-Deficit/Hyperactivity Disorder (ADHD) or Attention-Deficit Disorder (ADD) are often common comorbidities associated with having an Autism Spectrum Disorder or simply because they find that some tasks can quickly become too overwhelming for them.

  • Product Types: tea, honey sticks, capsules, balm, topicals, drinks, flowers, tinctures
  • Our Recommended Product for Autism: Focus CBD Essential Oil Roller

7. Plus CBD

Headquartered in Las Vegas, Nevada, Plus CBD only has one company goal: to provide as many people as possible with affordable, high-quality, and potent CBD-based products in order to enhance their everyday lives. Plus CBD understands the important role that CBD can play in the proper function of the mind and body, due to how vital the Endocannabinoid System (ECS) is in a variety of biological processes, such as appetite, pain sensation, mood, memory function, and biological fertility, among others.

With the claims of being the top-selling industrial hemp-derived CBD brand, there are many people worldwide that trust Plus CBD to provide them with a potent, safe and pleasant CBD experience, whether they are a new CBD user or they have been using CBD-based products for a long time. Plus CBD has to source their organic industrial hemp from Europe because of the immense scale of CBD that they require to fill all of their customer orders. This EU-sourced industrial hemp is carefully cultivated and harvested in nutrient-dense soil so that the end product is among the best in terms of quality and potency that you can get on the market today.

Plus CBD takes a “From Seed to Shelf™” stance when it comes to their numerous product lines. This means that the experienced and skillful Plus CBD employees are involved in every step of the cultivation and manufacturing process; from when the industrial hemp seeds are first planted in the ground to when the completed product is being packaged and distributed to Plus CBD’s customers. Plus CBD tests and manufactures their CBD products in a state-of-the-art facility that fully follow the Good Manufacturing Practices (GMP) guidelines that are set by the International Society for Pharmacoepidemiology (ISPE) and are enforced in the United States by the Federal Food, Drug, and Cosmetic Act (FDCA). This ensures that the CBD products produced by Plus CBD are among the safest CBD products on the market.

The CBD Oil Gummies that you can buy through Plus CBD are one of the top ten products that we highly recommend to those that place on the Autism Spectrum. These CBD gummies are available in two sizes and two different pleasant tasting flavors. Depending on your CBD needs, you can choose to buy a 30 count or a 60 count bottle of gummies in either Cherry Mango flavor or in their Citrus Punch flavor. These CBD gummies contain five milligrams of CBD per gummy (for 150 mg total CBD in the 30 count bottle; and 300 mg total in the 60 count) and are guaranteed to be gluten-free, to contain no genetically modified organisms (non-GMO), and are made from the aerial plant parts from organic industrial hemp sources.

Each of these gummies are expertly infused with the naturally-occurring and highly beneficial phytonutrients that come from the natural industrial hemp, such as: fatty acids, terpenes, and Vitamin E. Additionally, these gummies are very Phytocannabinoid-dense with compounds that can sometimes be lost in varying levels during some other, more inferior manufacturing processes, such as Cannabigerol (CBG) and Cannabichromenic Acid (CBCA).

  • Product Types: tinctures, soft gels, capsules, sprays, concentrates, balms, gummies
  • Our Recommended Product for Autism: CBD Oil Gummies

8. CBDfx

Headquartered in Chatsworth, California, CBDfx is a company that has really strong convictions when it comes to providing their customers with some of the best CBD-based products on the market today. CBDfx uses only ethically-sourced and locally-grown 100% organic industrial hemp that is cultivated on cruelty-free farms. CBDfx is one of the industry leaders in advocating for the use of CBD-based products for both mental and physical health, allowing some people to rely less heavily on more traditional over-the-counter pharmaceuticals that can have some negative impact on how well the user feels overall.

With more than 50 different CBD-based quality products on the market at a reasonable cost, CBDfx is sure to have something to offer anyone. New CBD users and veteran CBD users alike will easily be able to find a CBD product that suits their needs and their lifestyle when there is such a large selection of products to choose from. Some of the products that CBDfx have developed and are selling include: CBD oil pre-loaded vape pens, CBD oil vape cartridges, edibles, CBD isolate concentrates, and CBD-based pet healthcare products, among many others.

The CBD Capsules offered by CBDfx is what we strongly feel is one of the top ten best products for those that have a form of Autism Spectrum Disorder (ASD). These soft gel capsules contain a total of 750 mg of Full Spectrum CBD that was derived from organic industrial hemp. Each soft gel capsule contains 25 mg of CBD, and there are 30 soft gel capsules per bottle. The daily recommended dose for this product is one to two soft gel capsules per day, depending on your body’s tolerance to CBD and depending on the severity of your need for them.

Because each bottle contains a minimum of two weeks worth up to a month supply and due to the bottles being very favorably priced, these soft gel capsules really give you the best bang for your buck. Soft gel capsules are quick dissolving, allowing your body to access the Phytocannabinoids that they contain sooner. The potency, convenience, quality, and fast-acting properties are why these particular CBD soft gel capsules come so highly recommended by us.

  • Product Types: vape oils, vape pens, gummies, tinctures, capsules, oils, pet care, beverages, terpenes, edibles, concentrates
  • Our Recommended Product for Autism: CBD Capsules

9. Calm by Wellness

Calm by Wellness Co. is a Los Angeles, California-based CBD company that has been featured on NBC, CNN, NPR, FOX and The New York Times due to the quality and affordability of their numerous CBD products. Additionally, Calm by Wellness Co. was recently voted as having the best CBD products for pain, sleep, and anxiety according to their company website. For the CBD oil that the company uses in its products, the source only the highest possible grade, organically grown industrial hemp, which is cultivated in the nutrient-rich soil of Colorado’s farmland.

Calm by Wellness Co. has two different highly rated CBD-based product lines available for customers to choose from; their CBD extract tinctures and their edible CBD gummies. The different items that are in these two product lines are all made with Full Spectrum extracted CBD oil, natural hemp seed oil, fractionated coconut oil (which adds C8 Capric Acid and C10 Caprylic Acid–two very beneficial Medium-Chain Triglyceride fatty acids–to the ingredient blend), and high-quality essential oils, which naturally add a pleasant taste to the products. Calm by Wellness Co.’s CBD extracts are taken solely from the aerial plant parts of the industrial hemp, ensuring that you are getting the best possible CBD oils.

Calm by Wellness Co. is committed to providing its customers with some of the best CBD products that you can buy on the market today. As an added bonus, not only are their products of a very high-quality, but they are additionally very affordable compared to some other similarly high-quality CBD products that other companies put out. You can also take pride in the fact that when you buy from Calm by Wellness Co., you are spending your money with a company that gives back to their community and that cares about their employees and about preserving the earth’s natural resources. The company often donates to various non-profit organizations that serve people and their communities in a variety of ways.

The product from Calm by Wellness Co. that we feel would greatly benefit individuals that have placed on the Autism Spectrum is their CBD extract tinctures, which have a very nice dropper top for easy and convenient dosing. These CBD extract tinctures are available in two different delicious flavors (Peppermint and Strawberry Lemon-aid), and both flavors are available in three different strengths. The lowest strength option is their 250 mg of CBD per bottle, and the highest strength option is their 1000 mg of CBD per bottle, with a middle option of 500 mg of CBD per bottle. Regardless of which strength you feel is the best for you, each bottle contains 30 ml of total CBD tincture.

The recommended dosage is half of a dropper (0.5 ml), and there are approximately 60 doses per bottle. We recommend Calm by Wellness Co.’s CBD extract tincture because of how potent the product is. Because it is made with very high-quality ingredients, and it is a sublingual liquid, users will start to feel the effects of the CBD in a very short amount of time. This is because sublingual CBD liquids have a very high bioabsorbable rating, which means your body is able to spread it throughout your entire system quickly.